111年01月07日(星期五)12:30-13:30
【研究新知】DNA Methylation in Cancer Translational Medicine
生醫醫院 竹北院區八樓第三會議室
主講人：華聯生技 呂長益甲基化計畫首席研究員

Phalanx Biotech Group (華聯生技) is one of the global four microarray developers, providing genomics services (RUO/LDT/IVD), and genetic testing services in reproductive medicine (prenatal/postnatal CNV tests), population medicine (SNP tests), liver cancer ctDNA Methylation Test as well as scientific research OEM/ODM services.
 
Phalanx Biotech’s expertise is in expression profiling and genetic analysis which stems from its excellence as an original design manufacturer of gene expression microarrays, CytoOneArray®, targeted chromosomal microarrays, for prenatal and postnatal CNV (copy number variation) test services.
 
Apart from that, Phalanx Biotech also provides an all-in-one of value at risk for +17 common cancers and +13 chronic diseases by genetic tests from our SNP (single nucleotide polymorphism) microarray for personal health and risk assessment.
 
Especially, Phalanx pertains an exclusive patent for Liver DNA Methylation Test - A breakthrough genetic testing development by leveraging DNA methylation markers for early liver cancer detection and screening.


歡迎踴躍參加!